Olleedyen. The purpose otthis study was m determine whether 0 low procedural activated coagulation time In assocaled with a high rate of 6boepikl complication and to Idndty whether thaw is n atirettd coagalotiou line raises that may be associated with a low role of complications .
Bartgroud. In recent yeas the activated coagulation tote has come bib widespread me far menltmag andnagwletion In the c Bum laboratory. However. considerable controversy cadre; m to the standards by width to judge •• adequate•• nadcoagase" for bahwentlnal pocedmes .
Medkdr, From a Mid of 1,469 ensamive patients with paathmtm tromloalml coronary angioplty, we retroapea lively idaifed 103 (Group 1, 7% of the overall population) with adjust eoaplkalkm of death or emergency m urgent canary artery bypass graft surgery ad compared them with 400 patients without co mpBcolum (Group M . Group I patients had more high clot dkleal ehaemkrWim, such n type B and C leslom, alms III ad IV Millions, ream-nyowdW infraction and recent throutho171k trgamL Activated coagulation times was compared be .
Widespread application of interventional procedures performed in the cardiac catheterization laboratory has led to recognition of the importance of adequate anticoagulation. It has been customary to administer a large (10 .000 to 15,000 U) bolus dose of Imparin before percutaneous tanslumind coronary angioplasty ad. in some cases, to start a continuous heparin infusion if the procedure time is pro . longed, The activated coagulation time is a rapid assay of whole-blood clotting that has become part of the routine assessment of anticoagulation and heparin reversal in patients undergoing cardiopulmonary bypass surgery (1-9). In recent years, this test has also become part of the management of patients undergoing interventional procedures in the catheterization laboratory (10-14) .
However, considerable controversy remains as to the exact standards by which to judge "adequate" anticongula- twee., Grasp-I and II at Mnlke, alter tahninistrstko of 10,000 U of heproia and at da and at the procedure.
Results . There were ae dlfanaos In haselge activated coag . ukdou times between Groups I and U . Group I bad eigaileauuy , lower activated coagulation tbees after hepnk therapy and m the end or the procedure : 61% <250 s. 20% between 250 and 275 a, 11% between 275 and 300 a and 8% >300 a; 279 of Group U had activated eeagahdon tams 27% <250 s, 17% between 250 and 275 s, 35% between 275 and 300 a had 21% >300 a (p < 0.0001). Complications occurred k in pink" with And activated cow louses times <250 s but k only 0.3% of patients with find titivated coagulation dam >300 s.
Conclusions. A dYinlthed activated coagdation time response to an initial bolus of hpak is associated with major 61mapkell complications after coronary angleplmty, although patients with complications did have a higher risk before the procedure . H remains to be determined whether thus is an ideal "target" activated ewagulWou date for hltervndaal procedures .
( coronary artery bypass surgery . The patients with major complications (Group I) were compared with 400 patients with successful coronary angioplasty from the same time period (Group II). Group 11 patients comprised the first 40D patients in our patient data base of the original cohort of 1,469 patients with no procedural complications who had activated coagulation times measured at baseline, after heparin therapy and at the end of the procedure . As part of the normal routine in the catheterization laboratory, activated coagulation times were measured in all patients at baseline, before any heparin was administered . Patients then routinely received an intravenous bolus of 10,000 U of heparin, and activated coagulation time was again measured at least 5 min after the heparin bolus . All blood samples were drawn through the arterial sheath . All activated coagulation time measurements were performed with use of a HemoTec coagulation timer and high range cartridges with kaolin activator . Them cartridges are designed to give a response of -10D s far every I Uhel of heparin . Duplicate samples were ran, and the awaits of the two samples were averaged to provide a final value .
During the course of the subsequent coronary angioplasty procedure. additional heparin was administered, and addilioml procedural activated coagulation times were checked at the discretion of the operator . A final activated cagdalion time was measured at the end of the procedure, just before the patient left the catheleriration laboratory .
The following activated coagulation times were measured or calculated in each patient : baseline, after heparin therapy, at the end tithe procedure (final activated coagulation time) and activated coagulation time heparin response (defined as the activated coagulation time after heparin therapy minus the baseline activated coagulation time) . Measurements were compared between Groups I and 11 by a two-sample r test and by chi-square analysis . Measurements were com• pared between patients with and without complications at different activated coagulation time levels by chi-square analysis, and p < 0.05 was considered significant . 
Resells
The demographic characteristics of Groups I (major complications) and H (no major complications) (Table 1) were not significantly different between the two groups . However. there were clinical differences between both groups, as shown in Table 2 . Group 11 patients had more type A and fewer type C lesions anti were mom often in New York Hear Association functional classes 11 and W . with fewer patients in elm IV. In Group I there were more patients with a recent myocardial infarction who had undergone recent thrombolysis amt mole patients on a hope& drip before coronary angioplasty. Group I patients had also received significantly less procedural hapuin than Group II patients.
Activated coagulation times m baseline, after heparin therapy, and at the end of the procedure In Groups I and 11 are shown In Table 3 . There was no significant deference in baseline activated coagulation times between the two groups. but activated coagulation times after hapuin deeeapy and at the end of the procedure were significantly lower In Group 1, u was the activated coagulation time heparin response. Activated coagulation time values for each of the three major complications are also limed in Table 3 . Table 4 shows the uwnber of patients in Groups I and lI with and without complications at four different activated coagulation time levels after heparin therapy . Of or 56% of all Group 11 patients) did not . The differences between groups were significant (p < 0.000I). Table 5 shows the number of patients in Groups I and 11 with and without complications at four different final activated coagulation lime levels . A') 97 patients with final activated coagulation times <250 s had complications. Only three (0.8%) of 379 patients with final activated coagulation times 2275 s had complications, and only one 10.3%) of 317 patients with a final activated coagulation time ?300 s had complications. The differences between groups were significant (P < 0.000)) . Table 6 shows the number of patients in Groups I and It with and w(thout complications al four differ it heparin response levels. Of 333 patients in both groups who incmsed their activated coagulation times by < ISO s after a 103700-U hepn of heparin . 87 (representing 26% of the 333 patients at that activated coagulation time level, or 84 .5% or all Gimp I patients) had complications . Of 95 patients in both groups who increased their activated coagulation time by >175 s after a 10.000-U bolus of hepol in, 3 (representing 3% of the 95 patients at that activated coagulation lime level, or 2.9% of all Group I patients) had complications . The difereacea between groups were significant (p < 0 .0001) . Dlac, aa91W1 pranat Ydy. We documented that low procedural actlvated coagulation tunes are associated with a higher rate of In-hospital complications alter coronary angioplasty. Our Table 4 . Activated Coagulation Times Attar Heparin Therapy FERGUSON ET AL. 1063
ACT V ATFn rnannl ATION TIME AND oerrroMn AFT2n rttA data suggest that the risk of cunlplicalihms (urgent and emergency surgery . death) are substantially increased in patients with activated coagulation times <250 s after heparin then a2y or at the end of the procedure and in patients with an activated coagulation time response to 10,000 U of heparin <L515 s. Conversely, patients with activated coagulation times >275 s after heparin therapy or at the end of the procedure or an activated coagulation time response to 10,1010 U of heparin > 175 A had very few complications, All of our measurements were performed with a HemoTee automated coagulation timer, which uses a totally different measurement technique from the Hemochron system . the other commercially available automated coagulation timer. The results of these two different systems are not in any way comparable . and a target activated coagulation time of 3110 s rat tine machine is not the same as a target activated coagulation time of 300 s on the other (15) .
Interpremaan of results . One factor to consider in interpteting our results is that there was individual variation among physicians in our institution with regard to management of patients. aggressiveness with which procedural anticoagulation was approached and selection of patients for bypass surgery . The complications in Group I may be solely attributed to their higher incidence of clinical risk factors, many of which are associated with new or recent coronary thrombosis . The diminished activated coagulation time response in Group I may be a secondary phenomenon, and, in the face of lower procedural heparin doses, it cannot be concluded that the complications were related only to the lower activated coagulation time . The complications in these patients may have resulted from their high risk profile and a low final activated coagulation time as a result of less procedural heparin . In interpreting these results it is also important to remembar that this is A retrospective study. We compared a group with complications with a randomly selected subgroup of patients from the same time period without complications.
Because of this approach, the absolute percent of compiicadons at any given activated coagulation lime level or at any given response to an initial dose of heparin may be lower, but the trends exhibited In our data should still be valid . We the answer to these questions will regime prospective studies. In our own laboratory, however, we have adopted a fairly aggesuive approach to anticoagulation. Moat operators in our laboratories will attempt to achieve a HemTec Hemochron machine) in 89% ofpatients:11% ofpatients will require additional5eparia. Previous data (13) using a HemoTee machine instead of a Hemcchron machine suggest that the percent of patients achieving "adequate" anticoagulation is much lower. Only 13% of patients had an activated coagulation time >300 S atera 10,000•U bolus of aepatin . In the present study, 34% of the total group of patients had an activated coagulation time <250 s : 19% had an activated coagulation time between 250 and 275 s; 30% had an acti• vated coagulation lime between 275 and 300 s; and I S% had an activated coagulation time of >300 s. There are currently so real standards to date for determining what is truly "adequate -anticoagulation. Conclusions. I) There are no differences in baseline activated coagulation times between patients with and without major in-hospital complications after coronary angioplasty . Z) A diminished activated coagulation time response to heparin Is associated with major in-hospital complications after coronary angioplasty, although patients with complications did have higher prepeoceduro risk . 3)11 remains to be determined prospectively whether there is a threshold activated coagulation lime level that, if achieved during an intervemional procedure, would reduce the risk of major complications.
